• 1
    World Health Organization. 2012. [Cited 31 October 2012.] Available from URL:
  • 2
    Whiteford HA, Degenhardt L, Rehm J et al. Global burden of disease attributable to mental and substance use disorders: Findings from the Global Burden of Disease Study. Lancet 2013; 382: 15751586.
  • 3
    Fava M. Diagnosis and definition of treatment-resistant depression. Biol. Psychiatry 2003; 53: 649659.
  • 4
    Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am. J. Psychiatry 2006; 163: 19051917.
  • 5
    Lam RW, Kennedy SH, Grigoriadis S et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J. Affect. Disord. 2009; 117 (Suppl. 1): S26S43.
  • 6
    Bauer M, Pfenning A, Severus E, Whybrow PC, Angst J, Möller HJ, World Federation of Societies of Biological Psychiatry. Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J. Biol. Psychiatry 2013; 14: 334385.
  • 7
    Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: A meta-analysis. J. Clin. Psychiatry 2007; 68: 826831.
  • 8
    Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: A meta-analysis of placebo-controlled randomized trials. Am. J. Psychiatry 2009; 166: 980991.
  • 9
    Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 2002; 302: 381389.
  • 10
    Stark AD, Jordan S, Allers KA et al. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: Functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl) 2007; 190: 373382.
  • 11
    Berman RM, Marcus RN, Swanink R et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 2007; 68: 843853.
  • 12
    Marcus RN, McQuade RD, Carson WH et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 2008; 28: 156165.
  • 13
    Berman RM, Fava M, Thase ME et al. Aripiprazole augmentation in major depressive disorder: A double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009; 14: 197206.
  • 14
    Kamijima K, Higuchi T, Ishigooka J et al. Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: A randomized, double-blind, placebo-controlled study (ADMIRE study). J Affective Disorder. 2013; 151: 899905.
  • 15
    Thase ME, Trivedi MH, Nelson JC et al. Examining the efficacy of adjunctive aripiprazole in major depressive disorder: A pooled analysis of 2 studies. Prim. Care Companion J. Clin. Psychiatry 2008; 10: 440447.
  • 16
    Reimherr FW, Martin ML, Eudicone JM et al. A pooled MADRS/IDS cross-correlation analysis: Clinician and patient self-report assessment of improvement in core depressive symptoms with adjunctive aripiprazole. J. Clin. Psychopharmacol. 2010; 30: 300305.
  • 17
    Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960; 23: 5662.
  • 18
    Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979; 134: 382389.
  • 19
    Tohen M, Case M, Trivedi MH, Thase ME, Burke SJ, Durell TM. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: Rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J. Clin. Psychiatry 2010; 71: 451462.
  • 20
    El-Khalili N, Joyce M, Atkinson S et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: A multicentre, randomized, double-blind, placebo-controlled study. Int. J. Neuropsychopharmacol. 2010; 13: 917932.
  • 21
    Shelton RC, Andorn AC, Mallinckrodt CH et al. Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression. Int. Clin. Psychopharmacol. 2007; 22: 348355.
  • 22
    Pharmaceuticals and Medical Devices Agency in Japan. A randomized, double-blind, non-inferiority trial of escitalopram compared with paroxetine in Japanese patients with major depressive disorder. 2011. [Cited 30 April 2011.] Available from URL:
  • 23
    Nelson JC, Mankoski R, Baker RA et al. Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: A post-hoc, pooled analysis of two large, placebo-controlled studies. J. Affect. Disord. 2010; 120: 133140.
  • 24
    Romeral I, Pérez V, Ciudad A et al. Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysis. BMC Psychiatry 2013; 13: 51.